Overview

Anakinra for Preterm Infants Pilot

Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Phase I/II study of anakinra to prevent the impact of perinatal inflammation in extremely premature infants.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Monash Medical Centre
Collaborator:
Monash University
Treatments:
Interleukin 1 Receptor Antagonist Protein